Quince Therapeutics, Inc. (QNCX) Net income 2018–2025
Quince Therapeutics, Inc. (QNCX) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$84.0MFY2025 · since FY2018: -$12.5M → -$84.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$84.0M | -47.8% |
| FY2024 | -$56.8M | -81.1% |
| FY2023 | -$31.4M | +39.2% |
| FY2022 | -$51.7M | +42.6% |
| FY2021 | -$89.9M | -17.0% |
| FY2020 | -$76.8M | -107.8% |
| FY2019 | -$37.0M | -196.4% |
| FY2018 | -$12.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More QNCX financial trends
QNCX RevenueQNCX Net marginQNCX Gross profitQNCX Gross marginQNCX Operating incomeQNCX Operating marginQNCX Operating cash flowQNCX Free cash flowQNCX Capital expendituresQNCX Return on equityQNCX Stock buybacksQNCX Dividends paidQNCX Total assetsQNCX Total liabilitiesQNCX Shareholders’ equityQNCX overview →